

## Formulary Changes Update

The following changes to the MPC Approved Drug List (ADL) were approved by the Maryland Physicians Care Pharmacy & Therapeutics Committee. Please review these changes.

Key		
<b>UPPER CASE</b> = Brand Name Drugs	<b>Lower case</b> = Generic Drugs	<b>QL</b> = Quantity Limit
<b>PA</b> = Prior Authorizations	<b>ST</b> = Step Therapy	<b>AL</b> = Age Limit
<b>ADL</b> = Approved Drug List	<b>YOA</b> = Years of Age	<b>DD</b> = Discontinued Drug

### January 2021

**No Changes**

### February 2021

**No Changes**

### March 2021

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
ADAKVEO (crizanlizumab)	<i>Hematology</i>	Added to formulary; with PA	March 2021	N/A
SEVENFACT (coagulation factor VIIa)	<i>Hemostatics</i>	Added to formulary; with PA	March 2021	N/A
ZTLIDO 1.8% (lidocaine)	<i>Topical Anesthetics</i>	Added to formulary; No PA	March 2021	N/A

### April 2021

**No Changes**

### May 2021

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
GILENYA	<i>Neurologic Agent</i>	Removed from formulary	May 2021	AUBAGIO

(fingolimod)				
BREO ELLIPTA (fluticasone furoate- vilanterol)	<i>Pulmonary anti- inflammatory/Beta-Agonist combo</i>	Removed from formulary	May 2021	Fluticasone-salmeterol
TRULANCE (plecanatide)	<i>Gastrointestinal agent</i>	Removed from formulary	May 2021	AMITIZA
AMITIZA (lubiprostone)	<i>Gastrointestinal agent</i>	Added to formulary; No PA	May 2021	N/A
SPIRIVA (tiotropium bromide)	<i>Inhaled Long-Acting Muscarinic Antagonist</i>	Removed from formulary	May 2021	INCRUSE ELLIPTA
SPIRIVA RESPIMAT (tiotropium bromide)	<i>Inhaled Long-Acting Muscarinic Antagonist</i>	Removed from formulary	May 2021	INCRUSE ELLIPTA
<b>June 2021</b>				
<b>No Changes</b>				
<b>July 2021</b>				
<b>No Changes</b>				
<b>August 2021</b>				
<b>No Changes</b>				
<b>September 2021</b>				
<b>Drug Name</b>	<b>Therapeutic Class</b>	<b>Change</b>	<b>Effective Date</b>	<b>ADL Alternative (if applicable)</b>
SEMGLEE (insulin glargine)	<i>Insulin</i>	Add to formulary	September 2021	N/A
BASAGLAR (insulin glargine)	<i>Insulin</i>	Remove from formulary	December 2021	Semglee
TOUJEO (insulin glargine)	<i>Insulin</i>	Remove from formulary	September 2021	Semglee
ALBUTEROL HFA (Proair)	<i>SA Beta-agonist</i>	Add to formulary	September 2021	Albuterol HFA (Ventolin)
LEVALBUTEROL HFA	<i>SA Beta-agonist</i>	Remove from formulary	September 2021	Albuterol HFA

(Xopenex)				
SOFOSBUVIR/VELPATASVIR (Epclusa)		Add to formulary	September 2021	Mayvret
<b>October 2021</b>				
<b>No Changes</b>				
<b>November 2021</b>				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
LO LOESTRIN FE (norethindrone acetate/EE/ferrous fumarate)	<i>Contraceptive</i>	Remove from formulary	01/01/2022	Apri, Balziva, Microgestin FE
NATAZIA (estradiol valerate/denogest)	<i>Contraceptive</i>	Remove from formulary	01/01/2022	Apri, Balziva, Microgestin FE
AZOPT (brinzolamide)	<i>Antiglaucoma</i>	Remove from formulary	01/01/2022	Dorzolamide/Timolol, Latanoprost, Travoprost
COMBIGAN (brimonidine tartrate/timolol maleate)	<i>Antiglaucoma</i>	Remove from formulary	01/01/2022	Dorzolamide/Timolol, Latanoprost, Travoprost
TIMOPTIC (timolol maleate)	<i>Antiglaucoma</i>	Remove from formulary	01/01/2022	Dorzolamide/Timolol, Latanoprost, Travoprost
<b>December 2021</b>				
<b>No Changes</b>				